Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference

Published:2009-04-28 Issue:S10 Volume:115 Page:2247-2251
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Atkins Michael B.¹,Bukowski Ronald M.²,Escudier Bernard J.³,Figlin Robert A.⁴,Hudes Gary H.⁵,Kaelin William G.⁶,Linehan W. Marston⁷,McDermott David F.¹,Mier James W.¹,Pedrosa Ivan¹,Rini Brian I.²,Signoretti Sabina⁸,Sosman Jeffrey A.⁹,Teh Bin Tean¹⁰,Wood Christopher G.¹¹,Zurita Amado J.¹¹,King Laura¹²

Affiliation:

1. Beth Israel Deaconess Medical Center, Boston, Massachusetts

2. The Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, Ohio

3. Institut Gustave Roussy, Unite Immunotherapie, Villejuif, France

4. City of Hope Comprehensive Cancer Center, Duarte, California

5. Fox Chase Cancer Center, Philadelphia, Pennsylvania

6. Howard Hughes Medical Institute, Boston, Massachusetts

7. National Cancer Institute, Bethesda, Maryland

8. Brigham and Women's Hospital, Boston, Massachusetts

9. Vanderbilt‐Ingram Cancer Center, Nashville, Tennessee

10. Van Andel Research Institute, Grand Rapids, Michigan

11. M. D. Anderson Cancer Center, Houston, Texas

12. InforMEDical Communications Inc, Carlisle, Massachusetts

Funder

Genentech, Novartis Pharmaceuticals, Pfizer, Inc., and Wyeth Pharmaceuticals

National Institutes of Health, National Cancer Institute, Center for Cancer Research

Bayer and Novartis

Bayer and Pfizer

Amgen, GlaxoSmithKline, Pfizer, and Wyeth

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.24229

Reference19 articles.

1. National Cancer Institute. Kidney Cancer Home Page. Available at:http://www.cancer.gov/cancertopics/types/kidneyAccessed August 21 2008.

2. Renal-Cell Carcinoma

3. Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics

4. Sunitinib in Patients With Metastatic Renal Cell Carcinoma

5. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune Check Point CD40–CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells;Anticancer Research;2019-09

2. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT;Programme Grants for Applied Research;2018-06

3. Recent developments in small molecule therapies for renal cell carcinoma;European Journal of Medicinal Chemistry;2017-12

4. Biomarkers of Renal Cancer;Biomarkers of Kidney Disease;2017

5. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab;Journal of Clinical Oncology;2015-06-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3